New Research

April 9, 2018
MPN research

ASH Partners with UNC, a ClinGen grantee to Curate Genomic data for Blood Research

Publisher’s Note: My source at the American Society of Hematology (ASH) informed me that “initially MPNs aren’t going to be a primary focus, however, we expect […]
February 22, 2018

How MPN Blood Cancers outsmart the Immune System

AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE Researchers have discovered how some of the blood cancers known as myeloproliferative neoplasms (MPNs) evade the immune system.  Their […]
January 8, 2018
Celgene MPN drug Fedratinib

Celgene Acquires Impact Biomedicines, Adding Myeloproliferative Neoplasm Drug Fedratinib to Its Pipeline

Celgene Corporation (NASDAQ:CELG) and Impact Biomedicines today announced the signing of a definitive agreement in which Celgene will acquire Impact Biomedicines, which is developing fedratinib for […]
January 29, 2017
ruxolitinib and pegasys for treating MPNs

Dr Mesa and Dr Mikhael Discuss Latest MPN Research 2017

A Solid Summary on the Latest MPN Research in 2017 Drs. Joseph R. Mikhael and Ruben A. Mesa analyze and discuss pertinent clinical studies and late […]
October 18, 2016

Is a Cure for Blood Cancer Around the Corner?

New Leukemia Research in Phase I/IIa Clinical Trial Biosight, an Israeli pharmaceutical development company that is working on a cure for leukemia, this week closed an […]
September 21, 2016
hearing loss in PV

Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera

“Researchers found that the mean hemoglobin and hematocrit levels of the polycythemia vera group were 16.7 g/dL and 50.4%, respectively, vs 13.4 g/dL and 40.3% in […]
WordPress Security